Low-Dose SubQ Testosterone for Women’s Health

Low-Dose SubQ Testosterone, Muscle Support, and Chiropractic Care for Women – El Paso, TX Health Coach Clinic

Abstract: Testosterone is not a male-only hormone. Women make more of it than estrogen by weight throughout much of adult life, and levels fall with age. The strongest research supports low-dose therapy for postmenopausal women who have distressing low sexual desire. Subcutaneous injections place a tiny, consistent dose into the fat under the skin so blood levels can return to a normal female range. This Health Coach Clinic guide walks through how those shots work, who may be a candidate, how the dose is monitored, how muscle and bone support movement, and how health coaching, functional medicine, and integrative chiropractic care in El Paso can sit beside medical oversight so hormones, habits, and the spine are treated as one system.

Start With the Whole Person, Not Only a Lab Number

At Health Coach Clinic, the first question is not “What shot do you want?” It is “What is driving how you feel?” Sleep, stress, gut health, thyroid function, iron, medications, and spinal pain all change how a woman experiences midlife. Testosterone is one piece of that picture—not a stand-alone wellness product.

Women’s ovaries and adrenal glands make more testosterone than estrogen by mass across most of adult life. That output falls with age and drops further after the ovaries are removed (Davis et al., 2019; Hatzilabrou, 2025). When levels sit at the low end of a woman’s own range, some women notice a persistent, unwanted loss of desire. That problem has a name: hypoactive sexual desire disorder, or HSDD. Distress is the key. A quiet fade she does not mind is not the same as a loss that troubles her every day (Davis et al., 2019; Parish et al., 2021).

Pooled randomized trials in thousands of women show that restoring testosterone into the normal premenopausal range can improve desire, arousal, orgasm, pleasure, and satisfaction, and can lower sexual distress. The gains are real and consistent, but they are moderate, not magic, and a strong placebo response is part of the data (Islam et al., 2019; Hatzilabrou, 2025).

What Subcutaneous Injections Actually Do

A subcutaneous (SubQ) injection delivers medicine into the fatty layer just under the skin, not deep into muscle. Typical sites are the abdomen or outer thigh. The needle is short and thin. Oil-based testosterone—often testosterone cypionate—then seeps out slowly, which can keep blood levels steadier than a large intramuscular shot (FOLX Health, n.d.; Hone Health, 2024).

Think of it as a small, measured drip rather than a flood. Women need far less than men, often about one-tenth of a typical male dose. Clinics that use weekly SubQ cypionate often start in a low milligram range and then adjust to lab results, not a single “I feel worn out” day (Highland Longevity, n.d.; Hone Health Help Center, n.d.).

Keep these route facts in view:

• Most high-quality trials in women used patches, creams, or gels, not weekly shots (Hatzilabrou, 2025).
• One older implant study in women was positive for desire and bone density, but fixed pellets can overshoot the female range and cannot be turned down once placed (Hatzilabrou, 2025).
• No published milligram conversion exists from a 300-microgram patch to a SubQ syringe. The honest method is to dose to a measured blood level (Davis et al., 2019; Hatzilabrou, 2025).
• No testosterone product is FDA-approved for women in the United States. Use is off-label and requires informed consent (Cedars-Sinai, n.d.; Parish et al., 2021).

Some compounding programs offer low-concentration, prefilled single-dose syringes of testosterone cypionate in MCT oil for SubQ use. A ready syringe does not change the rules. Exposure still has to stay inside the female physiologic band (Hatzilabrou, 2025; Medivant Health, n.d.).

Dose to a Range, Then Coach the Rest of the Day

A healthy young woman often carries a total testosterone of about 15 to 46 ng/dL. That is a sliver of the male range. The job of therapy is to land inside that band and stay there (Hatzilabrou, 2025; Braunstein et al., 2011).

Pushing past the ceiling does not add extra desire. It can show up as acne, extra facial hair, scalp thinning, and, rarely, voice change (Islam et al., 2019; Parish et al., 2021).

A practical coaching-ready path looks like this:

• Confirm HSDD with real distress after other causes are checked.
• Review sleep, stress load, relationship context, and medicines that blunt desire (SSRIs above all).
• Treat genitourinary dryness and pain first when sex hurts; local estrogen, not a systemic androgen, is built for that problem (Parish et al., 2021).
• Draw baseline total testosterone with a sensitive LC-MS/MS test, not a routine immunoassay built for men (Rosner et al., 2007).
• Start low.
• Recheck the level and symptoms at about 8 to 12 weeks.
• Judge benefit at 3 to 6 months. If distressing low desire has not improved, stop rather than climb (Davis et al., 2019; Parish et al., 2021).

Baseline testosterone does not diagnose HSDD. It is a safety tool once treatment starts (Hatzilabrou, 2025). Health coaching then helps the plan stick: consistent injection timing, protein and strength work, sleep windows, and follow-up labs instead of dose-chasing between visits.

What the Body May Gain Beyond Desire

Sexual function is the outcome with the firmest trial support. Other claims need a quieter voice—the same honesty functional medicine asks of any supplement or protocol.

Muscle and strength. Testosterone helps muscle protein building in both sexes. Some women report better lean mass and training response when levels return to a mid-physiologic range. Large pooled trial data in women have not shown a robust body-composition effect at the low doses used for HSDD, so this is possible support, not a guarantee (Islam et al., 2019; Hatzilabrou, 2025).

Bone. One small two-year implant trial found faster gains in spine, hip, and total-body density when testosterone was added to estradiol. Guidelines still do not list bone as an approved reason to prescribe it because the study was small and not designed to prevent fractures (Davis et al., 1995; Wierman et al., 2014).

Energy and mood. Early and smaller studies sometimes showed better well-being. Dedicated trials and systematic reviews have been mixed or null for mood, fatigue, and cognition. Societies do not endorse testosterone as a general menopause tonic (Islam et al., 2019; Dichtel et al., 2020; Cedars-Sinai, n.d.).

Red blood cells. Testosterone can raise red-cell production. That is a monitoring issue at higher exposure, not a reason to treat ordinary anemia in women (Hatzilabrou, 2025).

For movement coaching, even a modest hold on muscle and bone matters. Stronger hip and core muscles help the pelvis stay level. Better bone quality supports the vertebrae that take daily load. Patients who can train without crashing energy keep the habits a health coach is trying to build (Jimenez, n.d.-a).

Safety While You Work on Root Causes

Short- and medium-term data at physiologic doses are generally reassuring for day-to-day effects: acne, extra hair, and oily skin. Those effects are usually dose-related and often fade if the dose is cut (Islam et al., 2019; Nachtigall et al., 2011).

What is missing is the long view. Adequately powered trials have not settled cardiovascular and breast outcomes over many years. That gap—not a proven harm signal—is a main reason no female product has been approved (Hatzilabrou, 2025; Cedars-Sinai, n.d.).

Therapy is not for pregnancy, breastfeeding, or people trying to conceive. Women with high baseline heart or breast-cancer risk need an especially clear shared decision (Hone Health Help Center, n.d.; Parish et al., 2021).

How Integrative Chiropractic Care and Coaching Fit

Hormones don’t exist apart from the skeleton or the nervous system. Low energy, weaker muscles, and slower recovery make spinal joints stiffer. Chronic pain and poor sleep raise stress load, which can worsen how a woman feels even when a lab is “in range.”

Clinical observation from Dr. Alexander Jimenez, DC, APRN, FNP-BC, CCST, CFMP, IFMCP, ATN, is consistent with restraint: female testosterone use is not a copy of male replacement. The strongest randomized evidence is still transdermal. SubQ use in women is an individualized, off-label choice. The goal is a physiologic range with a stop rule if desire does not improve (Jimenez, n.d.-b).

At Health Coach Clinic in El Paso, Texas (11860 Vista Del Sol, Suite 128), that observation sits inside a coaching and functional-medicine model. Care looks at food as medicine, gut and thyroid function, sleep, and daily movement. Integrative chiropractic care restores joint motion, posture, and neuromuscular control so strength work is safer. Health coaches help turn a plan into a week a woman can actually live.

Working with Dr. Jimenez means working with Dr. Maria Guadalupe Cardenas, MD, board-certified in internal medicine (NPI #1164426749, Texas MD License #J2933), with more than 40 years of experience as an internist. She serves as medical director and collaborative physician at the affiliated Injury Medical Clinic PA in the same El Paso location. In this multidisciplinary setup—common in integrative clinics—the internist provides medical direction, reviews labs and overall health, and helps keep off-label therapies within safe bounds. The chiropractor and nurse practitioner address structure and function. Functional medicine and coaching address habits. Rehabilitation rebuilds strength after injury, so a hormone plan is not asked to do the work of a weak core, an inflamed gut, or an unhealed disc (Jimenez, n.d.-a).

For a woman on low-dose testosterone, the practical payoff is simple.

• When the muscles around the spine hold better, adjustments last longer.
• If bone and lean mass are supported, training feels less fragile.
• If pain and sleep improve, desire often has a clearer path—without pretending testosterone is a cure for every midlife complaint.

A Clear Next Step

Testosterone therapy in women is not a wellness trend and not a male protocol scaled down by guesswork. It is a narrow, evidence-backed option for postmenopausal HSDD with distress, given at a female physiologic dose, watched with the right lab, and stopped if it does not help.

Subcutaneous injections can deliver that small, steady dose into fat under the skin. They still ask for discipline: start low, measure, stay inside the range, and pair the hormone with coaching—local treatment when dryness is the real problem, medication review when an antidepressant is the real problem, and hands-on musculoskeletal care when the spine and hips cannot carry the load.

If you want a root-cause evaluation that includes hormones, movement, and daily habits, start at Health Coach Clinic. Call (915) 613-5303 or (915) 412-6677. Telemedicine options may be available for appropriate follow-up. The goal is not a higher number on a printout. The goal is a woman who can move, recover, and feel like herself again.

---

References

Braunstein, G. D., Reitz, R. E., Buch, A., Schaefer, D., & Caulfield, M. P. (2011). Testosterone reference ranges in normally cycling healthy premenopausal women. The Journal of Sexual Medicine, 8(10), 2924–2934.

Cedars-Sinai. (n.d.). Testosterone therapy for women.

Davis, S. R., Baber, R., Panay, N., Bitzer, J., Perez, S. C., Nappi, R. E., Nijland, E., Simon, J., Vignozzi, L., & Wierman, M. E. (2019). Global consensus position statement on the use of testosterone therapy for women. The Journal of Clinical Endocrinology & Metabolism, 104(10), 4660–4666.

Davis, S. R., McCloud, P., Strauss, B. J., & Burger, H. (1995). Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas, 21(3), 227–236.

Dichtel, L. E., Carpenter, L. L., Nyer, M., Mischoulon, D., Kim, S., Cusin, C., Pedrelli, P., Fisher, L., Papakostas, G. I., & Fava, M. (2020). Low-dose testosterone augmentation for antidepressant-resistant major depressive disorder in women: An 8-week randomized placebo-controlled study. American Journal of Psychiatry, 177(10), 965–973.

FOLX Health. (n.d.). HRT subcutaneous vs. intramuscular injections.

Hatzilabrou, T. A. (2025). Testosterone therapy in women [White paper]. Worldborne Medical / Medivant Healthcare.

Highland Longevity. (n.d.). Women’s testosterone dosing guide.

Hone Health. (2024). Injectable testosterone cypionate for women.

Hone Health Help Center. (n.d.). Testosterone cypionate injection for women: Risks & benefits.

Islam, R. M., Bell, R. J., Green, S., Page, M. J., & Davis, S. R. (2019). Safety and efficacy of testosterone for women: A systematic review and meta-analysis of randomised controlled trial data. The Lancet Diabetes & Endocrinology, 7(10), 754–766.

Jimenez, A. (n.d.-a). Injury specialists. Injury Medical Clinic PA / Health Coach Clinic.

Jimenez, A. (n.d.-b). Subcutaneous testosterone for hormone balance therapy guide. Injury Medical Clinic PA.

Medivant Health. (n.d.). Andrenyx.

Nachtigall, L., Casson, P., Lucas, J., Schofield, V., Melson, C., & Simon, J. A. (2011). Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecological Endocrinology, 27(1), 39–48.

Parish, S. J., Simon, J. A., Davis, S. R., Giraldi, A., Goldstein, I., Goldstein, S. W., Kim, N. N., Kingsberg, S. A., Morgentaler, A., Nappi, R. E., Park, K., Stuenkel, C. A., Traish, A. M., & Vignozzi, L. (2021). International Society for the Study of Women’s Sexual Health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. The Journal of Sexual Medicine, 18(5), 849–867.

Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007). Utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. The Journal of Clinical Endocrinology & Metabolism, 92(2), 405–413.

Wierman, M. E., Arlt, W., Basson, R., Davis, S. R., Miller, K. K., Murad, M. H., Rosner, W., & Santoro, N. (2014). Androgen therapy in women: A reappraisal. An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 99(10), 3489–3510.